Fusions of Breast Carcinoma and Dendritic Cells as a Vaccine for the Treatment of Metastatic Breast Cancer
Abstract
The overall objective of this project is to study the safety, immunologic response and clinical effect of vaccinating breast cancer patients with dendritic cell (DC)/tumor fusions in conjunction with IL-12. The hypothesis underlying these studies is that tumor specific immunity can be generated by the presentation of breast tumor antigens in the context of the potent antigen presenting machinery of the DC. Task 1 of the approved Statement of Work is to assess fusions of human breast carcinoma cells with autologous DC by evaluating cytokine production (IL-12, IL-10) and potency of the fusions in generating tumor specific immunity in vitro (Months 1-12). Our results demonstrate that fusions of breast cancer cells with immature or mature DC are associated with induction of phenotypic characteristics consistent with DC maturation and activation. The fusion cells express IL-12, IL-10 and the chemokine receptor CCR7. The breast tumor/DC fusions were effective in stimulating i) autologous T cell proliferation, ii) cytokine production and iii) tumor specific T cell responses. Based on these findings, our plan is to now perform the Phase I/II clinical trial of breast cancer cell/DC fusions with IL-12 as a vaccine for patients with metastatic breast cancer (Tasks 2-4; Protocol included in Appendix A).
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2004
- Accession Number
- ADA429626
Entities
People
- Donald Kufe
Organizations
- Dana–Farber Cancer Institute